華仁藥業(300110.SZ)取得混合糖電解質注射液藥品註冊證書
格隆匯9月10日丨華仁藥業(300110.SZ)宣佈,公司於近日收到國家藥品監督管理局核准簽發的公司“混合糖電解質注射液”的《藥品註冊證書》。劑型為注射劑;規格為500ml;註冊分類為原化學藥品第6類;藥品有效期為12個月。
混合糖電解質注射液作為新一代新型糖電解質輸液,在外科領域的應用優勢十分明顯。混合糖電解質注射液能夠用於糖尿病、術後、燒傷、外傷和菌血症等患者的能量、水分及電解質的補充,可高效安全地補充能量,降低患者血糖波動和胰島素用量,減輕炎症反應,全面調節電解質紊亂,加快創面癒合。
混合糖電解質注射液由日本大冢株式會社開發,並於1994年在日本批准上市(數據來源:日本“獨立行政法人醫藥品醫療器械綜合機構”網站)。在國內,目前江蘇正大豐海製藥有限公司、中國大冢製藥有限公司、麗珠集團利民製藥廠批等三家公司取得該品種註冊批件(數據來源:國家藥品監督管理局網站)。
2019年在中國城市公立醫院銷售額為52,315萬元(數據來源:米內網)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.